Claude Designs Proteins, Hits 14 of 15 Targets
Anthropic had Claude design protein binders for 15 targets; Adaptyv Bio and Twist Bioscience validated hits in the wet lab, with 14 targets succeeding.
AI drug discovery News and Analysis
12 verified stories covering AI drug discovery, product updates and industry developments.
Aureka raises $100M for biology models
Aureka Biotechnologies raised a $100 million Series B to train biological foundation models and connect AI agents with wet-lab feedback.
DeepMind turns AI toward biosecurity
Google DeepMind and Isomorphic Labs laid out a bioresilience program that uses frontier AI to prevent misuse, detect outbreaks and speed medical countermeasures.
OpenAI tests biology judgment, and GPT-5.6 clears only 31.5%
GeneBench-Pro uses messy biological datasets to test whether models can make research decisions, not just answer textbook questions.
Anthropic Moves From Claude Science Into Drug Discovery
Anthropic launched Claude Science and said it will pursue drug discovery programs for neglected diseases that large pharma often ignores.
GPT-5.4 lifts Chan-Lam yields in wet-lab tests
OpenAI and Molecule.one used GPT-5.4 to identify TEMPO as an additive, raising average Chan-Lam coupling yields from 16.6% to 25.2% across high-throughput experiments.
OpenAI updates GPT-Rosalind for life sciences
OpenAI’s life-science model adds agentic coding, research plugins and NGS analysis tools, while cutting token use by 31% on long quantitative biology tasks.
Waypoint Bio raises $20M for AI-validated cell therapies
Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.
Isomorphic raises $2.1B to push AI-designed drugs toward clinic
DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
Isomorphic Labs raises $2.1B to scale AI drug design
DeepMind spinout Isomorphic Labs says its drug design engine is repeatable, and investors are funding the long push from partnerships into clinical proof.
AI-Designed Drug Wins First Clinical Trial
Insilico Medicine's rentosertib (ISM001-055) has completed a Phase IIa trial with statistically significant efficacy data, marking the first time a drug with both target and molecule fully generated by AI has shown positive human results.
Anthropic closes first acquisition ever, buys biotech startup Coefficient Bio for $400 million
Anthropic has made its first acquisition since its founding, purchasing stealth-mode biotech startup Coefficient Bio for $400 million in an all-stock deal, signaling a strategic shift from selling general-purpose model capabilities to building deep domain expertise in life sciences.